General Genomics exploits a novel evolutionary approach to engineer enzymes for the industrial, agricultural and biomedical markets. Our unique approach towards directed evolution endows our enzymes with biomolecular properties desired by commercial sectors. General Genomic’s near-term goal consists of engineering a protein therapeutic that treats gout and prevents tumor lysis syndrome. Mid-term goals of the company consist of engineering proteins valuable to the industrial markets such as detergents, food/beverage processing, animal feed, crop production, biofuels and others.